In April 2023, India’s securities regulator cleared Portea Medical to raise up to ₹1,000 crore ($104 million, at $1 ≈ ₹96.0 as of 18 September 2026, Trading Economics) on the stock exchanges. Nearly three years on, the home healthcare company has not opened that issue — instead, in April 2024, it went back to the same set of private investors for a rights issue worth less than a fifth of that sum.
Portea, founded in 2013 by the husband-and-wife team of K Ganesh and Meena Ganesh, built one of India’s earliest at-home nursing and doctor-visit networks, then widened into medical equipment and pharmacy supply to keep the lights on. Its FY25 numbers show a company that has stopped bleeding as fast as it once did, but a stock-exchange listing that once looked imminent is, on the public record, going nowhere.
Quick facts
| Company | Portea Medical (parent: Healthvista India Limited) |
| Founded | 2013, Bengaluru |
| Founder(s) | K Ganesh and Meena Ganesh |
| Businesses | Home healthcare services (nursing, physiotherapy, doctor visits), medical equipment sale/rental, pharmacy supply via subsidiary Medybiz Pharma |
| Latest FY revenue | ₹160 crore, FY25 (year to March 2025) |
| Latest FY profit/loss | Net loss of ₹19 crore, FY25 |
| Listed | Private. SEBI cleared a ₹1,000 crore IPO in April 2023; not taken forward as of January 2026 |
| Market value / last valuation | Not publicly disclosed in any filing or report reviewed for this piece |
| Key shareholders / CEO | Accel, Ventureast and International Finance Corporation among the largest institutional backers; Vaibhav Tewari is CEO, Meena Ganesh is Chairperson |
What they do
Portea Medical sells healthcare delivered inside a patient’s own home rather than a hospital bed. A family books a nurse, physiotherapist, doctor consultation, lab test or post-surgery care visit through Portea, and the company sends a caregiver instead of admitting the patient. Alongside the visits, Portea sells and rents medical equipment such as oxygen concentrators, BiPAP machines and nebulisers, and it runs a pharmacy-supply arm, Medybiz Pharma, that procures and resells medicines and consumables. The customer base spans elderly and chronic-care patients who want to avoid repeat hospital admissions, post-operative patients discharged early, and hospitals themselves, which refer or outsource home follow-up to Portea rather than building the capability in-house (Inc42, DRHP filing coverage, July 2022).
The origin
K Ganesh and Meena Ganesh were not first-time founders when they started Portea. Meena had trained at IIM Calcutta, cut her teeth at PricewaterhouseCoopers and Microsoft, then co-founded Customer Asset, which she sold to ICICI Bank, before building and selling the education company TutorVista to Pearson. K Ganesh, an IIM Calcutta graduate as well, had co-founded Customer Asset and TutorVista alongside her and went on to found the startup incubator Growth Story, which later seeded BigBasket, BlueStone and HomeLane (The Morning Context, July 2022; IIM Calcutta alumni profile). The insight behind Portea, launched in 2013, was narrower and more personal: India’s hospital infrastructure was concentrated in a handful of cities and expensive to occupy for routine, recurring care, while a large and ageing urban middle class needed exactly that kind of routine care — nursing, physiotherapy, chronic disease management — delivered at home instead. Rather than build hospitals, Portea built a logistics and staffing layer on top of hospitals that already existed, partnering with them for referrals rather than competing with them for beds.
The struggle years
Portea’s growth years were followed by a stretch where the topline simply would not move, and the losses did. In FY23, revenue from operations fell 3.3% to ₹145 crore from ₹150 crore in FY22, while the net loss widened by 32% to ₹53 crore from ₹40 crore a year earlier — a rare combination of shrinking sales and growing losses at the same time (Entrackr, April 2024). The following year did not bring relief: FY24 revenue slipped further, to ₹139 crore, even as the company continued to lose money, with the loss for that year later disclosed at ₹37 crore (Entrackr, January 2026). Two straight years of flat-to-declining revenue meant that every rupee of expense was working harder against the company: its cost-to-revenue ratio rose to ₹1.42 spent for every ₹1 of revenue earned in FY23, before easing only slightly to ₹1.29 in FY24 (Entrackr, April 2024 and January 2026). Running alongside this financial stagnation was an unresolved public listing: Portea’s parent, Healthvista India, had filed its draft IPO papers in June 2022 and secured SEBI’s approval in April 2023, but by its own most recent financial disclosures had still not opened the issue — a nearly three-year gap between regulatory clearance and an actual listing, with no fresh RHP filed in the interim (Entrackr, January 2026; Inc42, April 2023).
The turning point
The clearest before-and-after moment in Portea’s recent history is not a product launch but a listing that quietly did not happen. Healthvista India’s IPO, as approved by SEBI in April 2023, was structured to raise ₹1,000 crore in total — a ₹200 crore fresh issue plus an offer for sale of roughly 5.63 crore shares worth about ₹800 crore, aimed at giving early backers a partial exit on the exchanges (Inc42, April 2023; BW Disrupt, April 2023). A year later, in April 2024, instead of opening that offer to the public, Portea raised $20 million (about ₹165.8 crore) by issuing 6.92 crore Series D1 compulsorily convertible preference shares at ₹23.96 apiece — on a rights basis, to its existing shareholders only (Entrackr, April 2024; Inc42, April 2024). The gap between the two numbers is the story: a public raise sized at ₹1,000 crore was quietly substituted with a private one worth roughly a sixth of that, and by the time Portea reported its FY25 results in January 2026, Entrackr noted plainly that “the company has since not taken any further steps” on the IPO it had SEBI’s blessing to launch.
The money behind it
Portea has raised capital in distinct phases rather than one continuous climb, with its investor base staying remarkably consistent across a decade:
- Series A, December 2013: $8 million from Accel and Ventureast, with Qualcomm Ventures also participating — the round that funded Portea’s initial city-by-city expansion.
- Series B, September 2015: $37.5 million led by Accel, joined by the International Finance Corporation (IFC, part of the World Bank Group), Qualcomm Ventures and Ventureast — at the time the largest funding round in India’s home healthcare segment (DC Advisory; TechCrunch, September 2015).
- Series C, November 2017: $26 million led by new investors Sabre Partners and MEMG CDC, with existing backers Accel, IFC, Qualcomm Ventures and Ventureast all returning — money the company said would fund a wider range of “out of hospital” services (TechCrunch; Medianama, November 2017).
- Rights issue (Series D1), April 2024: $20 million (₹165.8 crore) from existing shareholders, priced at ₹23.96 per compulsorily convertible preference share — raised explicitly ahead of, and ultimately in place of, the planned IPO (Entrackr, April 2024).
Cumulative funding is reported inconsistently across trackers: Entrackr’s January 2026 reporting puts total capital raised at approximately $123 million, while other databases such as Tracxn and Clay cite lower lifetime totals in the $95–114 million range, most likely reflecting different treatment of debt, ESOPs or unannounced bridge rounds. No source reviewed for this piece discloses a current valuation for Portea — that figure is treated as confidential in every filing and report available publicly, and is left out here rather than estimated.
How it makes money
Portea earns in three distinct ways, and the mix has shifted over time as the company leaned harder into higher-margin services:
- Home healthcare services — nursing, physiotherapy, doctor consultations, palliative, geriatric, post-operative and maternal care visits billed per session or as care packages. This was roughly 60% of revenue around the time of its 2022 IPO filing (The Morning Context, July 2022) and stood at ₹95 crore, or 59% of FY25 operating income, up 16% year-on-year (Entrackr, January 2026).
- Medical equipment sales and rental — oxygen concentrators, BiPAP machines and nebulisers sold or leased to home-care patients. Combined with pharmacy-linked product sales, this line brought in ₹56 crore in FY25, up 14% year-on-year (Entrackr, January 2026).
- Pharmaceutical procurement and resale — run through subsidiary Medybiz Pharma, supplying medicines and consumables to home-care patients and, per the company’s own IPO papers, intended to receive working-capital funding from IPO proceeds (Inc42, DRHP coverage, 2022).
The part outsiders get wrong is assuming home healthcare is asset-light. It is not: every visit requires a trained nurse or therapist on payroll or contract, travel time between homes eats into billable hours, and equipment has to be bought, serviced and depreciated whether or not it is rented out that month. That is why, even after two years of revenue growth, Portea’s FY25 EBITDA margin was still negative 6.9%, and its return on capital employed was negative 40.5% (Entrackr, January 2026) — the business has moved from deeply unprofitable to modestly unprofitable, not yet to profitable.
The numbers
Figures below are revenue from operations and net loss as reported to the Ministry of Corporate Affairs and covered by Entrackr; all amounts in ₹ crore.
| Year | Revenue (₹ crore) | Net loss (₹ crore) |
| FY23 | 145 | 53 |
| FY24 | 139 | 37 |
| FY25 | 160 | 19 |
- FY23: revenue down 3.3% year-on-year, loss up 32% — EBITDA margin negative 27.5%, ROCE negative 94% (Entrackr, April 2024).
- FY24: revenue down further to ₹139 crore, loss narrowed to ₹37 crore, cost-to-revenue ratio ₹1.29 per rupee earned (Entrackr, January 2026).
- FY25: revenue up 15% to ₹160 crore, loss cut 49% to ₹19 crore — EBITDA margin negative 6.9%, ROCE negative 40.5%, cost-to-revenue ratio improved to ₹1.12 per rupee earned (Entrackr, January 2026).
- FY25 cost lines: employee benefits ₹52.5 crore (down 4.5% year-on-year); cost of materials consumed ₹52 crore (up 21%); consultancy charges ₹44 crore (up 7%); advertising ₹7.5 crore (up 25%); total expenses roughly flat at ₹179 crore (Entrackr, January 2026).
Where the money comes from
- By service line, FY25: healthcare services ₹95 crore (59% of operating income); equipment and product sales ₹56 crore (35%); the remainder from other operating income (Entrackr, January 2026).
- By geography: the company’s own 2022 IPO filing described operations across 16 cities and partnerships with more than 70 hospitals, spanning metros such as Bengaluru, Delhi-NCR, Mumbai, Pune, Chennai, Kolkata and Hyderabad as well as smaller cities including Vijayawada, Lucknow, Coimbatore, Jaipur and Indore (Inc42, DRHP coverage, 2022).
- Scale claimed by the company: more than 1 million patients served and roughly 700,000 annual home visits as of its FY23 disclosures (Entrackr, April 2024) — a company-reported figure, not independently audited for this piece.
- The surprise: a business built on nursing visits now earns more than a third of its revenue from selling and renting hardware — oxygen concentrators, BiPAP machines, nebulisers — a product line that grew faster than the core service line in FY25 (14% versus roughly flat volume growth implied by the numbers).
The risks
- Persistent unprofitability despite falling losses. Even after a 49% cut in FY25, Portea still lost ₹19 crore on ₹160 crore of revenue, and its EBITDA margin remains negative — the company needs several more years of cost discipline or revenue growth before it reaches breakeven on current trends (Entrackr, January 2026).
- A stalled public listing that leaves the company reliant on existing backers. With SEBI approval for a ₹1,000 crore IPO obtained in April 2023 and not acted on, Portea funded itself via a rights issue restricted to existing shareholders in April 2024 — a structure that works only as long as those backers keep writing cheques, and offers no path to a public market valuation or exit in the near term (Entrackr, January 2026; Entrackr, April 2024).
- Regulatory friction over governance structure. SEBI required Portea’s founders to be reclassified as “promoters” — a formal governance status carrying disclosure and lock-in obligations — after objecting to the company’s original claim that it had no identifiable promoter, a friction point that Inc42 reported could recur for other founder-led startups attempting to list without a traditional promoter structure (Inc42, April 2023).
The takeaway
Regulatory approval to go public is not the same thing as being ready to go public, and Portea’s last three years are a reminder of the gap between the two. A company can clear every box a regulator asks for — file the prospectus, fix the governance structure, get the observation letter — and still choose, quietly, not to walk through the door, because the underlying numbers are not yet a story public investors would reward. What Portea did instead was slower and less visible: cut its cost-to-revenue ratio, halve its losses, and keep the business funded through the people who already believed in it. That is a less dramatic outcome than an IPO, but for a company still recording a negative return on capital, it may have been the more honest one.
Frequently asked questions
What does Portea Medical do?
Portea provides healthcare services delivered at a patient’s home, including nursing, physiotherapy, doctor consultations and chronic or post-operative care, alongside selling and renting medical equipment and supplying medicines through its subsidiary Medybiz Pharma.
Who founded Portea Medical and when?
Portea was founded in 2013 by K Ganesh and Meena Ganesh, a husband-and-wife team who had previously built and sold Customer Asset to ICICI Bank and TutorVista to Pearson.
Did Portea Medical’s IPO happen?
No. SEBI approved a ₹1,000 crore IPO for Portea’s parent, Healthvista India, in April 2023, but as of Portea’s most recent public financial disclosures in January 2026, the company had not opened the issue and had instead raised further private capital through a rights issue in April 2024.
Is Portea Medical profitable?
Not yet. Portea narrowed its net loss to ₹19 crore in FY25 from ₹37 crore in FY24, on revenue of ₹160 crore, but its EBITDA margin and return on capital employed both remained negative that year.
Who are Portea Medical’s key investors?
Accel and Ventureast have backed Portea since its 2013 Series A, joined over subsequent rounds by the International Finance Corporation, Qualcomm Ventures, Sabre Partners and MEMG CDC.
Sources
Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).
- Entrackr, “Portea’s revenue stays flat in FY23; losses grow 32%,” April 2024
- Entrackr, “Exclusive: IPO-bound Portea Medical raises $20 Mn via right issue,” April 2024
- Entrackr, “Portea posts Rs 160 Cr revenue in FY25; narrows losses,” January 2026
- Inc42, “Healthtech Startup Portea Files DRHP To Raise INR 1,000 Cr Via IPO,” July 2022
- Inc42, “Healthtech Startup Portea Receives SEBI Nod For INR 1,000 Cr IPO,” April 2023
- BW Disrupt, “SEBI Approves Portea Medical’s IPO Worth Rs 1000 Cr,” April 2023
- Inc42, “IPO-Bound Portea Medical Secures $20 Mn Via Rights Issue,” April 2024
- The Morning Context, “The Portea IPO looks like a rescue act,” July 2022
- TechCrunch, “Portea Medical, One Of India’s Largest Home Care Providers, Gets $37.5M From Accel,” September 2015
- DC Advisory, deal announcement on Portea Medical Series B investment from Accel Growth and International Finance Corporation, 2015
- TechCrunch, “Indian home healthcare platform Portea Medical raises $26M Series C,” November 2017
- Medianama, “Portea Medical raises $26M in series C funding,” November 2017
- Business Standard, “Portea Medical elevates Meena Ganesh as chairperson; Vaibhav Tewari is CEO,” August 2021
- Trading Economics, USD/INR exchange rate, 18 September 2026
Found an error? Write to us and we’ll correct it in the open, dated, on the piece.